Mechanisms of resistance to alkylating agents

Cytotechnology

Volumn 27, Issue 1-3, 1998, Pages 165-173

  Damia, G ^a   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alkylating agents; Resistance

Indexed keywords

ALKYLATING AGENT; APOPTOSIS; CANCER THERAPY; DETOXIFICATION; DNA ADDUCT; DNA REPAIR; DRUG RESISTANCE; METALLOTHIONEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

EID: 0032412943     PISSN: 09209069     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-94-017-2374-9_10     Document Type: Article

References (91)

1. Anthoney DA, Mcllwrath AJ, Gallagher WM, Edlin AR and Brown R (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381.
2. Armitage, JO and Antman, KH (1995) High-dose cancer therapy: pharmacology, hematopoietins, stem cells, Williams and Wilkins, Baltimore: Ed. 2.
3. Beith J, Hartley J, Darling J and Souhami R (1997) DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase. Br J Cancer 75: 500-505.
4. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W and Yarosh D (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783-788.
5. Bodell WJ, Tokuda K and Ludlum DB (1988) Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Cancer Res 48: 4489-4492.
6. Boise LH, Gonzalez Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G and Thompson CB. (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
7. Bolton MG, Hilton J, Robertson KD, Streeper RT, Colvin OM and Noe DA (1993) Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. Drug Metab Dispos 21: 986-996.
8. Bramson J, O'Connor T and Panasci L (1995) Effect of alkyl-N-purine DNA glycosylase overexpression on cellular resistance to bifunctional alkylating agents. Biochem Pharmacol 50: 39-44.
9. Branch P, Aquilina G, Bignami M and Karran P (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652-654.
10. Branch P, Hampson R and Karran P (1995) DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. Cancer Res 55: 2304-2309.
11. Brown SJ, Kellett PJ and Lippard SJ (1993) Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261: 603-605.
12. Bruhn SL, Pil PM, Essigmann JM, Housman DE and Lippard SJ (1992) Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 89: 2307-2311.
13. Bubley GJ, Ogata GK, Dupuis NP and Teicher BA (1994) Detection of sequence-specific antitumor alkylating agent DNA damage from cells treated in culture and from a patient. Cancer Res 54: 6325-6329.
14. Bunting KD and Townsend AJ (1993) Mafosfamide sensitivity in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase ('tumor ALDH'). Proc Am Ass Cancer Res 34: 270 (Abstract).
15. Buser K, Joncourt F and Altermatt H-J (1997) Breast cancer: Pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristic. Ann Oncol 8: 335-341.
16. Chaney SG and Sancar A (1996) DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 88: 1346-1360.
17. Chao CC, Huang SL, Lee LY and Lin Chao S (1991) Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II) Biochem J 277: 875-878.
18. Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ and Cherian MG (1993) Metallothionein in testicular germ cell tumors and drug resistance. Clinical correlation. Cancer 72: 3029-3035.
19. Chu G and Chang E (1990) Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 87: 3324-3328.
20. Ciaccio PJ, Tew KD and LaCreta FP (1991) Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid. Biochem Pharmaco!42: 1504-1507.
21. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni G and D'Incalci M (1997) Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 65: 130-137.
22. Colella G, Bonfanti M, D'Incalci M and Broggini M (1996) Characterization of a protein recognizing minor groove bindersdamaged DNA. Nucleic Acids Res 24: 4227-4233.
23. Cotter TG and Samali A (1997) Oncogenes, apoptosis and cancer. FORUM 7: 4-17.
24. D'Incalci M and Sessa C (1997) DNA minor groove binding ligands: a new class of anticancer agents. Exp Opin Invest Drugs 6 (In Press).
25. Dabholkar M, Vionnet J, Bostick Bruton F, Yu JJ and Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708.
26. Damia G, Imperatori L, Citti L, Mariani L and D'Incalci M (1996) 3-methyladenine-DNA-glycosylase and O6-alkyl guanine-DNA-alkyltransferase activities and sensitivity to alkylating agents in human cancer cell lines. Br J Cancer 73: 861-865.
27. De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Sire E, Azzani D, Stanzione S, Parodi S, D'Incalci M, Russo P and Broggini M (1997) DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 76.
28. De Vita, VTJ, Hellman, S and Rosemberg, SA (1997) Cancer. Principles and practice of oncology, Lippincott-Raven, Philadelphia: Ed. 5.
29. Dirven HA, van Ommen B and van Bladeren PJ (1994) Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 54: 6215-6220.
30. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bloch CA and Castle VP (1994) Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259.
31. Drummond JT, Anthoney A, Brown R and Modrich P (1996) Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 271: 19645-19648.
32. Eastman A (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cisdichloro(ethylenediamine)platinum(II) Biochemistry 22: 3927-3933.
33. Egyhazi S, Bergh J, Hansson J, Karran P and Ringborg U (1991) Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer 27: 1658-1662.
34. El-Deiry WS (1996) p53, p21 WAF1/CIP1 and the control of cell proliferation. In Cell cycle control and apoptosis in malignant disease, Thomas NSB (ed) pp. 55-75. Bios Scientific Publishers: Oxford.
35. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC and Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217-1228.
36. Engelward BP, Dreslin A, Christensen J, Kurahara C and Samson L (1996) Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have encreased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J 15: 945-952.
37. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, Jr and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55: 1649-1654.
38. Ferrandina G, Scambia G and Damia G (1997) Glutathione S-transferase activity in epithelial ovarian cancer: Association with response to chemotherapy and disease outcome. Ann Oncol 8: 343-350.
39. Ferrando AA, Velasco G, Campo E and Lopez Otin C (1996) Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Res 56: 1746-1750.
40. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269.
41. Gibbons GR, Kaufmann WK and Chaney SG (1991) Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis 12: 2253-2257.
42. Gottlieb TM and Oren M (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287: 77-102.
43. Greenblatt MS, Bennett WP, Hollstein M and Harris CC. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
44. Hannun YA (1997) Apoptosis dilemma of cancer chemotherapy. Blood 89: 1845-1853.
45. Hemminki K and Kailama S (1986) Reactions of nitrogen mustards with DNA. IARC Sci Publ 55-70.
46. Hemminki K (1994) DNA adducts of nitrogen mustards and ethylene imines. IARC Sci Publ 313-321.
47. Hill BT, Shellard SA, Fichtinger Schepman AM, Schmoll HJ and Harstrick A (1994) Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. Anticancer Drugs 5: 321-328.
48. Hilton J (1984) Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44:5156-5160.
49. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336.
50. Hotta T, Saito Y, Fujita H, Mikami T, Kurisu K, Kiya K, Uozumi T, Isowa G, Ishizaki K and Ikenaga M (1994) O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 21: 135-140.
51. Huang JC, Zambie DB, Reardon JT, Lippard SJ and Sancar A (1994) HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91: 10394-10398.
52. Hurley LH, Reynolds VL, Swenson DH, Petzold GL and Scahill TA (1984) Reaction of the antitumor antibiotic CC-1065 with DNA: structure of a DNA adduct with DNA sequence specificity. Science 226: 843-844.
53. Johnson SW, Shen D, Pastan I, Gottesman MM and Hamilton TC (1996) Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatomacell lines. Exp Cell Res 226: 133-139.
54. Karran P and Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839.
55. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM and Modrich P (1993) An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 90: 6424-6428.
56. Kaufmann WK (1989) Pathways of human cell post-replication repair. Carcinogenesis 10: 1-11.
57. Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH and Lazo JS (1988) Overexpression of metallothionein confers resistance to anticancer drugs. Science 241: 1813-1815.
58. Kondo S, Barnett GH, Hara H, Morimura T and Takeuchi J (1995) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006.
59. Lasorella A, lavarone A and Israel MA (1995) Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance. Cancer Res 55: 4711-4716.
60. Lohrer H and Robson T (1989) Overexpression of metallothionein in CHO cells and its effect on cell killing by ionizing radiation and alkylating agents. Carcinogenesis 10: 2279-2284.
61. Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL and Chaney SG (1994) Enhanced replicative bypass of platinumDNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 54: 3500-3505.
62. McA'Nulty MM and Lippard SJ (1996) The HMG-domain protein Ixrl blocks excision repair of cisplatin-DNA adducts in yeast. Mutat Res 362: 75-86.
63. McDonald ER, Wu OS, Waldman T and El Deiry WS (1996) Repair Defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res 56: 2250-2255.
64. Minn AI, Rudin CM, Boise LH and Thompson CB (1995) Ex-pression of bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910.
65. Modrich P and Lahue R (1996) Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu Rev Biochem65: 101-133.
66. Moscow JA, Swanson CA and Cowan KH (1993) Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 68: 732-737.
67. Mu D, Park CH, Matsunaga T, Hsu DS, Reardon JT and Sancar A (1995) Reconstitution of human DNA repair excision nuclease in a highly defined system. J Biol Chem 270: 2415-2418.
68. Nichols AF, Schmidt WJ, Chaney SG and Sancar A (1992) Limitations of the in vitro repair synthesis assay for probing the role of DNA repair in platinum resistance. Chem Biol Interact 81: 223-231.
69. Niimi S, Nakagawa K, Yokota J, Tsunokawa Y, Nishio K, Terashima Y Shibuya M, Terada M and Saijo N (1991) Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes. Br J Cancer 63: 237-241.
70. Panasci L, Henderson D, Torres Garcia SJ, Skalski V, Caplan S and Hutchinson M (1988) Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res 48: 1972-1976.
71. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562.
72. Povirk LF and Shuker DE (1994) DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res 318: 205-226.
73. Ryan JJ, Danish R, Gottlieb CA and Clarke MF (1993) Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13: 711-719.
74. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon tumorderived cell line. Proc Natl Acad Sci USA 89: 4495-4499.
75. Sklar MD and Prochownik EV (1991) Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res 51:2118-2123.
76. Sladek NE and Landkamer GJ (1985) Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res 45: 1549-1555.
77. Sreerama L and Sladek NE (1993) Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 45: 2487-2505.
78. Strandberg MC, Bresnick E and Eastman A (1982) The significance of DNA cross-linking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem Biol Interact 39: 169-180.
79. Sumantran VN, Ealovega MW, Nunez G, Clarke MF and Wicha MS (1995) Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res 55: 2507-2510.
80. Tew KD, Bomber AM and Hoffman SJ (1988) Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625.
81. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 54: 4313-4320.
82. Torres Garcia SJ, Cousineau L, Caplan S and Panasci L (1989) Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem Pharmacol 38: 3122-3123.
83. Tsuchida S and Sato K (1992) Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 27: 337-384.
84. Vaisman A and Chaney SG (1995) Induction of UV-damage recognition protein by cisplatin treatment. Biochemistry 34: 105-114.
85. Waldman T, Lengauer C, Kinzler KW and Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 (see comments). Nature 381: 713-716.
86. Waxman DJ (1990) Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy-a review. Cancer Res 50: 6449-6454.
87. Wu ZN, Chan CL, Eastman A and Bresnick E (1992) Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents. Cancer Res 52: 32-35.
88. Yarosh DB, Barnes D and Erickson LC (1986) Transfection of DNA from a chloroethylnitrosourea-resistant tumor cell line (MER+) to a sensitive tumor cell line (MER-) results in a tumor cell line resistant to MNNG and CNU that has increased O-6-methylguanine-DNA methyltransferase levels and reduced levels of DNA interstrand crosslinking. Carcinogenesis 7: 1603-1606.
89. Yonish Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347.
90. Yu JJ, Dabholkar M, Bennett WP, Welsh JA and Mu CJB-B (1996) Platinum-sensitive and platinum-resistant ovarian cancer tissue show differences in the relationships between mRNA levels of p53, ERCC1 and XPA. Int J Oncol 8: 313-317.
91. Zwelling LA, Anderson T and Kohn KW (1979) DNA-protein and DNA interstrand cross-linking by cis- and trans-platinum(II) diamminedichloride in L1210 mouse leukemia cells and relation to cytotoxicity. Cancer Res 39: 365-369.